Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline-Reference-Cited by-同舟云学术

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Published:2023-01 Issue:1 Volume:34 Page:33-47
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sessa C.,Balmaña J.,Bober S.L.,Cardoso M.J.,Colombo N.,Curigliano G.,Domchek S.M.,Evans D.G.,Fischerova D.,Harbeck N.,Kuhl C.,Lemley B.,Levy-Lahad E.,Lambertini M.,Ledermann J.A.,Loibl S.,Phillips K.-A.,Paluch-Shimon S.

Funder

Manchester Biomedical Research Centre

Associazione Italiana per la Ricerca sul Cancro

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference117 articles.

1. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels;Lee;Genet Med,2019

2. The complex genetic landscape of familial breast cancer;Melchor;Hum Genet,2013

3. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2;Gabai-Kapara;Proc Natl Acad Sci U S A,2014

4. Breast cancer risk genes - association analysis in more than 113,000 women;Dorling;N Engl J Med,2021

5. A population-based study of genes previously implicated in breast cancer;Hu;N Engl J Med,2021

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review;Cancer Treatment Reviews;2024-11

2. Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene;Genetics in Medicine;2024-10

3. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?;npj Breast Cancer;2024-09-05

4. PROTOCOLOS DE RASTREAMENTO E DIAGNÓSTICO PRECOCE DO CÂNCER GINECOLÓGICO;International Journal of Health Management Review;2024-09-04

5. Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2;Critical Reviews in Oncology/Hematology;2024-09